Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

Combination therapy with cadonilimab, a first-in-class bispecific antibody targeting both PD-1 and CTLA-4, and chemotherapy offers encouraging antitumor activity and manageable safety as a first-line ...

MUD HCT is associated with better survival outcomes and fewer severe complications compared to haploidentical HCT in acute ...

Reclassified disease response criteria at 28 days of treatment for acute graft-vs-host disease (GVHD) improved prediction of 6-month nonrelapse mortality (NRM) compared with conventional criteria in ...

October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from the US FDA. This period saw important full and accelerated drug approvals ...

In clinical practice, dose adjustment for SSAs is a common strategy used to manage patients with neuroendocrine tumors (NETs). The primary reason for escalating the dose is to achieve better symptom ...

The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

The investigational oral KRAS G12D inhibitor VS-7375 (GFH375) has shown a promising early safety profile and preliminary antitumor activity in pretreated patients with advanced solid tumors harboring ...

Jaume Capdevila, MD, Vall d'Hebron Hospital, discusses the final analysis of the phase 3 COMPETE trial (NCT03049189). Data ...